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Abstract
The activating immunoreceptor NKG2D promotes elimination of infected or malignant cells by cytotoxic lymphocytes
through engagement of stress-induced MHC class I-related ligands. The human cytomegalovirus (HCMV)-encoded
immunoevasin UL16 subverts NKG2D-mediated immune responses by retaining a select group of diverse NKG2D ligands
inside the cell. We report here the crystal structure of UL16 in complex with the NKG2D ligand MICB at 1.8 A ˚ resolution,
revealing the molecular basis for the promiscuous, but highly selective, binding of UL16 to unrelated NKG2D ligands. The
immunoglobulin-like UL16 protein utilizes a three-stranded b-sheet to engage the a-helical surface of the MHC class I-like
MICB platform domain. Intriguingly, residues at the center of this b-sheet mimic a central binding motif employed by the
structurally unrelated C-type lectin-like NKG2D to facilitate engagement of diverse NKG2D ligands. Using surface plasmon
resonance, we find that UL16 binds MICB, ULBP1, and ULBP2 with similar affinities that lie in the nanomolar range (12–
66 nM). The ability of UL16 to bind its ligands depends critically on the presence of a glutamine (MICB) or closely related
glutamate (ULBP1 and ULBP2) at position 169. An arginine residue at this position however, as found for example in MICA or
ULBP3, would cause steric clashes with UL16 residues. The inability of UL16 to bind MICA and ULBP3 can therefore be
attributed to single substitutions at key NKG2D ligand locations. This indicates that selective pressure exerted by viral
immunoevasins such as UL16 contributed to the diversification of NKG2D ligands.
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Introduction
Human cytomegalovirus (HCMV) is a b-herpesvirus that causes
lifelong asymptomatic infections in healthy individuals but
endangers the lives of immunocompromised individuals and very
young children [1]. Cytotoxic lymphocytes such as CD8 T cells
and natural killer (NK) cells are essential for the control of HCMV
infection [1–4]. HCMV possesses a broad arsenal of immune
evasive strategies that counteract cellular immunosurveillance and
ensure long-term persistence in infected human hosts [2,5–8]. One
such strategy is the degradation of MHC class I molecules in order
to subvert presentation of HCMV-derived peptide antigens to
CD8 ab T cells [2,6,8]. However, in line with the ‘missing-self-
hypothesis’, impaired MHC class I expression results in a
decreased engagement of MHC class I-specific inhibitory NK cell
surface receptors and thus may facilitate NK cell-mediated lysis of
the infected cells [9]. NK cell activity, however, is not solely
controlled by receptors that inhibit NK cell activation, but rather
is determined by the integration of signals from both inhibitory
and activating NK cell receptors [10–12]. A potent activating
receptor that mediates NK surveillance of stressed cells such as
infected or malignant cells (‘induced-self’ or ‘stressed-self’ recog-
nition) is NKG2D (natural-killer group 2, member D) [11,13,14].
NKG2D is a C-type lectin-like homodimer expressed on NK cells
and cytotoxic T cells [15]. In humans, NKG2D transmits
activating (NK cells) or co-stimulatory (CD8 ab T cells and cd
T cells) signals via the associated DAP10 adaptor [16] and is
triggered through engagement of cell stress-inducible MHC class
I-related ligands belonging to the diverse MIC (MHC class I chain
related molecule) and ULBP (UL16 binding protein) families. Two
MIC (MICA and MICB) and six ULBP proteins (ULBP1-6) are
currently known [2,13,14,17–19]. The ULBP proteins are also
sometimes referred to as ‘retinoic acid early transcript’ proteins
(RAET; ULBP1/RAET1I, ULBP2/RAET1H, ULBP3/
RAET1N, ULBP4/RAET1E, ULBP5/RAET1G and ULBP6/
RAET1L). To thwart an antiviral NKG2D-mediated immune
response, HCMV counteracts virally induced cellular expression
of NKG2D ligands by means of several immunoevasins [2,5,8].
HCMV-encoded glycoproteins UL16 and UL142 selectively
prevent the surface expression of MICB, ULBP1 and ULBP2
(UL16) and MICA (UL142), respectively, through intracellular
retention [2,20–23]. The significance of evasion from NKG2D-
mediated immunosurveillance is further highlighted by the recent
discovery that the HCMV gene UL112 is transcribed into a
microRNA (miRNA) which specifically suppresses translation of
MICB mRNA [24]. Although all NKG2D ligands share a MHC
class I-like a1a2-platform domain [25–28] that binds NKG2D,
UL16 does not bind to MICA, ULBP3, ULBP4 or ULBP5
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are highly homologous in sequence (83% identical residues in the
a1a2 region) but much more distantly related to the ULBP
molecules (that share 21–29% identical residues in the a1a2
region with the MICs and 38–59% amino acid sequence identity
among each other), which were originally discovered in a screen
for UL16-binding proteins [18,32].
In order to elucidate the structural basis for the ability of UL16
to engage highly diverse NKG2D ligands and to compare this
promiscuous binding mode to that of NKG2D, we determined the
structure of the UL16 ectodomain in complex with the a1a2-
platform domain of MICB (MICBpf) at 1.8 A ˚ resolution (Table 1).
We also expected structural insights into the selective UL16
binding to MICB (but not MICA) and to some ULBP family
members as selective pressure exerted by viral immunoevasins
such as UL16 may have contributed to the diversification of
NKG2D ligands [2,17,23]. We find that UL16, which possesses no
structural homology to NKG2D, nevertheless employs a NKG2D-
like binding mode to interact with MICB. Our results also offer
structural explanations for the selective UL16 binding to some
NKG2D ligands, and illustrate how the immunological arms race
between a persistent pathogen and the human immune system
may have driven the evolution of proteins of both, virus and host.
Results
Structure of UL16
UL16 is a heavily glycosylated 50 kDa type I transmembrane
glycoprotein whose structure could not be predicted from its
primary sequence [33]. In order to obtain soluble and homoge-
neously glycosylated protein for our structural and surface
plasmon resonance (SPR) studies, we expressed the UL16
ectodomain in Chinese hamster ovary (CHO) Lec 3.2.8.1 cells
[34]. UL16 was co-crystallized with MICBpf refolded from E. coli
inclusion bodies (see Materials and Methods). The UL16 ectodomain
folds into a modified version of the immunoglobulin (Ig)-like
domain (Figure 1A). The presence of nine b-strands, arranged in
two antiparallel b-sheets (formed by b-strands A, G, F, C, C9,C 0
and b-strands D, E, B, respectively) and a central disulfide bond
linking b-strands B and F clearly classifies it as a variable (V-type)
Ig-like domain [35–37]. In contrast to classical V-type Ig domains,
however, UL16 also has an additional N-terminal ‘‘plug’’ (amino
acids 27–50), formed by a two-stranded antiparallel b-sheet (b-
strands X1 and X2) and a short 310-helix (Figure 1A). The plug
covers the concave side of the AGFCC9C0 b-sheet and is
covalently linked to the Ig-like core with a disulfide bond between
b-strands X2 and F. The UL16-MICBpf complex was partially
Table 1. Data collection and refinement statistics (Molecular
Replacement).
Native
Data collection
Space group P212121
No. of complexes in asymmetric unit 2
Unit cell dimensions
a, b, c (A ˚) 58.1, 104.2, 146.8
Resolution (A ˚) 50-1.8
Rmerge 7.2 (49.4)
a)
I/sI 16.9 (3.4)
Completeness (%) 98.7 (97.5)
Redundancy 8.9 (6.9)
Wilson Factor (A ˚2) 24.1
Refinement
Resolution (A ˚) 50-1.8
No. reflections
Measured 733339
Unique 82272
Rwork 17.7
Rfree (test set of 5%) 21.3
No. of non-H atoms 5980
Protein 5084
Carbohydrates 196
PEG8000 49
Acetate 12
Water 639
Average isotropic B factor (A ˚2)
Protein main chain 28.0
Protein side chain 34.1
Carbohydrates (NAG) 41.5
PEG8000 55.6
Acetate 65.0
Water 39.1
R.m.s deviations
Bond lengths (A ˚) 0.006
Bond angles (u) 1.057
Ramachandran regions
b)
most favorable (%) 97.4
Allowed 2.6
Outliers 0
a)Highest resolution shell is shown in parenthesis. A single crystal was used to
assemble the data set.
b)Determined with Coot [49] version 0.5.
doi:10.1371/journal.ppat.1000723.t001
Author Summary
Cytotoxic lymphocytes such as natural killer (NK) cells or
CD8 T cells have the ability to detect and destroy cells
infected by viruses. They therefore are tools on which the
human immune system critically depends in order to
control viral infections. To avoid discovery by cytotoxic
lymphocytes and to allow for longtime persistence in the
human host, the human cytomegalovirus (HCMV) has
developed a multitude of immune evasive strategies that
are mediated by so-called immunoevasins. We present
here a structure-function analysis of one of the best-known
HCMV immunevasins, UL16, and its interaction with a
cellular ligand for NK cells, MICB. The normal function of
MICB is to activate NK cells by engaging the most well-
known NK receptor, NKG2D. Our results provide molecular
evidence for the strategy used by UL16 to disable NK cell
activation. In a rare example of structural mimicry that has
likely arisen through convergent evolution, UL16 mimics a
central binding motif of the structurally unrelated NKG2D
protein. This allows UL16 to engage and disable several
diverse NKG2D ligands, while others have apparently
evolved to escape recognition by UL16 through alteration
of key residues at strategic locations.
Complex Structure of HCMV UL16 and MICB
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acetylglucosamine (NAG) molecules attached to glycosylation sites.
While there is no evidence for O-linked glycosylation, our electron
density maps provide clear evidence for the presence of NAGs at
seven out of eight putative N-glycosylation sites (asparagines 35,
41, 68, 84, 95, 101 and 132). Modeling experiments show that
native glycosylation would effectively shield much of the UL16
surface from solvent (Figure 1B). In particular, the outward-facing
AGFCC9C0 b-sheet and the N-terminal plug are expected to be
mostly covered with glycans in the fully glycosylated protein. By
contrast, the solvent-exposed face of the DEB b-sheet is devoid of
glycans and available for interactions with other proteins.
Structure of MICB
The extracellular region of MICB consists of two structural
domains, the a1a2-platform domain (MICBpf) and the C-type Ig-
like a3-domain [25]. The a3-domain is present only in the MIC
family members of NKG2D ligands, but not among members of
the ULBP family [17,25–28]. Our SPR measurements (Figure 2
and Table S1) yielded almost identical dissociation constants (KD)
for the complexes formed by UL16 with MICBpf (KD=66 nM) or
the complete MICB ectodomain (KD=67 nM), respectively.
Together with a previous report [29], this demonstrates that the
a3-domain does not contribute to UL16 binding. Based on these
results, only MICBpf was expressed and used for co-crystallization
with UL16. As previously reported for the unliganded MICB [25],
MICBpf folds into a structure that closely resembles MHC class I
molecules, with two long parallel a-helices, contributed by
domains a1 and a2, arranged above an eight-stranded antiparallel
b-sheet (Figure 1B; for nomenclature of domains and secondary
structure elements see Figure 3A). Comparison of MICBpf with
the structure of the unliganded MICB ectodomain [25] shows that
the platform domain remains essentially unchanged upon
engagement of UL16 (root-mean-square deviation of 1.4 A ˚ for
172 common Ca atoms). Although minor differences are seen
within three surface-exposed loops and a short N-terminal helix
(a0), the residues in these regions have elevated temperature
factors and do not contact UL16.
The UL16-MICB interface
UL16 primarily engages MICBpf via a predominantly hydro-
phobic, glycan-free (see also Ref. [29]) surface comprised of its
DEB b-sheet and the adjacent b-strand A, with additional contacts
provided by the DE-loop (connecting b-strands D and E) and four
amino acids (aa 160–163) at the C-terminus (Figures 3B and 4).
This surface interacts with the two long parallel helices at the top
of the MICB platform domain and the b5b6-loop connecting b-
strands b5 and b6 of MICB (Figures 3A and 4), shielding an area
of 2194 A ˚ 2 from solvent. With the exception of the MICB region
that corresponds to the peptide-binding groove in MHC class I
proteins, the contact area contains few interfacial solvent-filled
cavities. The complex features good surface complementarity
(Sc=0.77) and is highly curved (planarity=4.0) [38,39]. Its overall
organization resembles a saddle with two stirrups (UL16) that is
mounted on horseback (MICBpf) (Figure 4A, see also Figure 1B).
The saddle is formed by the DEB b-sheet, whereas the stirrups are
contributed by the DE-loop and the C-terminus on either side of
the sheet. To facilitate discussion of interactions, we have divided
the UL16-MICB interface into three regions (A, B and C,
Figure 4). Contact region A, which is located at the center of the
complex and mostly hydrophobic in nature, contributes 54% of
the total contact area. Interactions predominantly involve residues
within the DEB b-sheet and b-strand A of UL16. Eight UL16
residues (Trp54, Leu56, Met59, Ile61, Ile63, Tyr125, Leu110 and
Leu114) define a compact hydrophobic face that interacts with
non-polar regions of MICBpf residues in its central a3-helix.
Figure 1. Structure of UL16 in complex with MICBpf. (A), Ribbon drawing of the structure of UL16. The portion of UL16 belonging to the V-
type immunoglobin [35] superfamily fold is colored blue, and the N-terminal ‘‘plug’’ is colored red. Glycosylated asparagines (nitrogen atoms dark
blue, oxygen atoms red) and attached N-acetylglucosamine residues (yellow) are shown as ball-and-stick models. The grey N-acetylglucosamine
residue attached to Asn35 has high temperature factors and was therefore not included in the refinement. Disulfide bonds are shown in green. (B)
Structure of the UL16-MICBpf complex. UL16 is colored as in (A), MICBpf is shown in orange. In order to visualize the native glycosylation of UL16,
modeled glycans are shown in yellow as ball-and-stick models with a semitransparent surface. See Materials and Methods for details.
doi:10.1371/journal.ppat.1000723.g001
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UL16 Asp112 and MICB Lys152 and a number of mostly water-
mediated hydrogen bonds (Figure 4B). Contact region B, with
23% of the total contact area, is located at one end of the DEB b-
sheet and within the DE-loop of UL16. UL16 residues in this
region contact several acidic residues (Glu64, Asp65 and Glu68) in
the a1-helix of MICBpf, mostly via polar interactions (Figure 4C).
Contact region C, which contributes 23% to the total contact
area, is located on the other side of the UL16 saddle. Here, the C-
terminus of the UL16 ectodomain interacts with the b5b6-loop
and the N-terminus of MICBpf via a mixture of hydrophilic and
hydrophobic contacts (Figure 4D). The overall architecture of the
complex, with its large contact area and substantial number of
interactions between contacting residues, indicates tight binding,
which is in agreement with our SPR data that place the affinity of
UL16 for MICBpf at 66 nM (Figure 2 and Table S1).
Comparison with the NKG2D-MICA complex
A crystal structure of the NKG2D homodimer bound to MICB
is unavailable. However, the NKG2D structure in complex with
the highly homologous MICA protein [26] shows that both
NKG2D monomers make extensive contacts with the long helices
at the top of the MICA a1a2-platform domain. The NKG2D-
MICA complex buries a surface area of 2170 A ˚ 2, which is almost
exactly the same area buried in the UL16-MICBpf complex. A
superimposition of the two complexes demonstrates that contacts
formed by UL16 overlap substantially with those made by one
NKG2D monomer (Figures 5A, B). One could therefore envision
Figure 2. Kinetic and equilibrium SPR analyses of UL16 interactions with MICB. (A,B) Kinetic analyses of UL16 binding to covalently
immobilized MICB proteins comprising domains a1 and a2 only (MICBpf) (A), and domains a1, a2 and a3 (B). Each individual analyte concentration
was injected twice and data are representative of at least two separate experiments with similar results. Double-referenced sensorgrams (shown in
color) are overlaid with fits of a ‘‘1:1 binding with mass transfer’’ model (black lines). Corresponding residual plots below the sensorgrams show the
kinetic-fit range and absolute deviation (D) of data points from curve fit values. The red arrow and the red highlighted area of the sensorgram series
indicate data used to determine averaged (AVG) equilibrium (Eq) response values (Eq-Response AVG) for equilibrium analysis. (C,D) Equilibrium
analysis of UL16 binding to MICBpf (C) and MICB domains a1, a2 and a3 (D). Averaged equilibrium response values (red squares) are plotted against
injected UL16 concentrations and fitted to a ‘‘1:1 Langmuir isotherm’’ model (black line). The shaded boxes contain additional information about
setup details (black font) and measured parameters from kinetic (blue font) and equilibrium analysis (red font).
doi:10.1371/journal.ppat.1000723.g002
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[18], perhaps even displacing it from its ligands. While the higher
affinity of UL16 for MICB and ULBP1 (KD values of 66 and
12 nM, respectively) (Figures 2 and S1 and Table S1) compared
with the respective affinities of NKG2D for the same ligands (KD
values of 0.8 and 1 mM, respectively)[40] would support this
Figure 3. Amino acid sequences of NKG2D ligands, NKG2D, and UL16. (A) Sequence alignment of NKG2D ligands. Sequences of the a1a2-
platform domains of NKG2D ligands MICA*01, MICB*02, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5 and ULBP6 are included in the alignment. The
alternative RAET nomenclature of ULBP proteins is indicated. Secondary structure elements as observed in the structure of MICBpf in complex with
UL16 were assigned by DSSP [62] and are represented with cylinders (helices) and arrows (b-strands) below the alignment. Helices are named as
described in [28]. Residues shaded in blue contact UL16 in the UL16-MICBpf complex. Residues shaded in salmon contact the salmon-colored NKG2D
monomer (Figures 5A, B) in the MICA-NKG2D and ULBP3-NKG2D complex structures [26,28]. Residues shaded in green contact the green NKG2D
monomer (Figures 5A, B) in the MICA-NKG2D and ULBP3-NKG2D complex structures. Residues marked with a red triangle indicate substitutions
between MICA and MICB in regions that contact UL16 in the MICBpf-UL16 complex. The ULBP5 residue boxed in cyan was recently shown to be the
major determinant for diminished binding to NKG2D and UL16 [31]. Disulfide bridges and corresponding cysteines are represented with magenta
lines. Gaps are indicated by (2). (B) Structural mimicry of UL16. Shown are relevant portions of the sequences of the green human NKG2D monomer
[26,28] (Figures 5A, B) and UL16. Secondary structure elements as observed in the structure of MICBpf in complex with UL16 and MICA in complex
with NKG2D [26], respectively, were assigned and represented as described in panel A. The five residues marked with numbered black boxes below
the sequence define the central binding motif that engages MICBpf or, in the case of NKG2D, MICA [26], in a similar manner (Figure 5C). Residues with
the same number superimpose in space, although they are located in different regions in the protein sequences. Residues shaded in yellow and
orange form contacts with MICA in the case of NKG2D [26] and with MICBpf in the case of UL16, respectively. NKG2D residues in red contact ULBP3 in
the ULBP3-NKG2D complex [28]. Residues that augment the central binding motif, performing similar functions in the UL16-MICBpf and NKG2D-MICA
complexes are marked with filled light red boxes below the sequence. An example is shown in Figure 5C. Disulfide bridges are represented with
magenta lines. Hexagons mark the seven UL16 asparagine residues linked with glycans as observed in the UL16-MICBpf complex.
doi:10.1371/journal.ppat.1000723.g003
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cell and is therefore unlikely to compete with NKG2D for ligand
binding [2,17,20,21].
The detailed comparison of the central contact regions in each
case reveals that, despite having entirely different folds, NKG2D
and UL16 use an almost identical pattern of amino acid side
chains to engage their ligands (Figure 5C, see also Figures 3B and
S2). In UL16, this pattern includes the MICB-contacting residues
Ile63, Lys123 and Tyr125, while NKG2D uses an identical
pattern of residues, Ile182, Lys197, and Tyr199, to form very
similar contacts with MICA. Remarkably, although the three side
chains are contributed by different structural elements in each
case, their position in space overlaps closely (Figure 5C). This is
also true for two additional UL16 residues, Leu110 and Leu114,
which are hydrophobic in nature and overlap with chemically
related NKG2D residues Met184 and Tyr152 (Figure 5C).
Together, the five residues constitute a predominantly hydropho-
bic binding motif that is common to NKG2D and UL16
(Figures 5B, C), and that forms the center of the interaction with
the MIC molecules. This central binding motif is augmented by
additional contacts, such as those mediated by UL16 residue
Tyr65 and NKG2D residue Ser195, that perform similar functions
in the UL16-MICBpf and NKG2D-MICA [26] complexes
(Figures 3B and 5C). Since all MICA and MICB residues
contacted by this central binding motif are identical, and since
the structures of MICA and MICB superimpose well in this region,
we conclude that UL16 mimics a key structural motif of NKG2D
with an entirely different fold in order to engage MICB.
Furthermore, we consider it likely that the central binding motif
of UL16 also plays an important role in the recognition of other
NKG2D ligands, for which structures of complexes with UL16 are
not yet available.
Discussion
Bacterial and viral pathogens often interfere with cellular
activities and immunosurveillance processes to enhance their
survival and effectiveness [41]. This is typically achieved by
virulence factors, which imitate the function of a host protein by
mimicking its key structural features. In the majority of such cases,
pathogens first hijack and then manipulate host genes to produce
structurally homologous versions of host proteins [41–45]. Thus,
virulence factors and host proteins are derived from the same origin
and arise from divergent evolution. However, structural mimics can
also be generated through convergent evolution. Although differing
in evolutionary origin and three-dimensional structure, the
virulence factors have in this case evolved to mimic key structural
features of cellular proteins. Examples for the latter strategy, which
Figure 4. Interaction between UL16 and MICBpf. (A), Ribbon tracing of the complex using the color code from Figure 1. Also shown in the
lower right corner of panel A is a schematic representation of the ‘‘saddle on horseback’’ arrangement between UL16 and MICB. (B–D), The three
major contact regions A, B and C of the complex. Nitrogen, oxygen and sulfur atoms are colored blue, red, and yellow, respectively. Hydrogen bonds
and salt bridges are represented with dashed green and red lines, respectively, and hydrophobic contacts (distance,4.0 A ˚) are shown as dashed
magenta lines. The dashed blue line indicates p-p interactions of two arginine guanidinium groups. Water molecules are shown as red spheres.
doi:10.1371/journal.ppat.1000723.g004
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exceedingly rare and are limited to a small number of virulence
factors [41,46,47]. The comparison of HCMV UL16 with human
NKG2D, reveals a striking example of convergent evolution [41]. A
set of five predominantly hydrophobic core residues on the UL16
surface precisely mimics a set of five equivalent residues in the
central region of the interface used by the structurally unrelated
immunoreceptor NKG2D to interact with its ligands.
As this central binding motif represents only a portion of the
total interface between NKG2D and its ligands (Figure 5), one
may wonder why UL16 mimics just this particular structural motif
of NKG2D. McFarland et al. reported that residues constituting
this motif (Tyr152, Met184 and Tyr199) form the basis for the
highly degenerate ligand recognition mode of NKG2D [40,48].
They proposed a ‘‘rigid adaptation’’ mechanism, in which a rigid
binding site on NKG2D uses the same set of predominantly
hydrophobic core residues to make diverse interactions with a
series of chemically and structurally distinct ligand residues. As an
example, Tyr199 and Tyr152 of NKG2D can accommodate
residues as diverse as Ala, Met or Phe at ligand position 159 [40]
(Figures 3A and S2). Mimicry of these core residues likely enables
UL16 to employ this binding mechanism of NKG2D to contact a
similar set of ligands. The ‘‘rigid adaptation’’ concept is
furthermore supported by the finding that UL16 engages its
ligands via a rigid b-sheet, which does not allow for much
conformational flexibility. The ligand residues contacted by
NKG2D and UL16 in MICA and MICB, respectively, are
Asp65, Thr155, Ala159, Ala162, Asp163 and the hydrophobic
portions of the Arg/His158 side chain (Figures 3A and 5C and S2)
[26,40,48]. Since NKG2D and UL16 both evolved the same
central binding motif in order to contact this specific set of ligand
residues, the latter likely represent binding hot spots in MICA and
MICB [48]. Furthermore, these residues probably are also of
major importance for interactions with ULBP molecules
(Figures 3A and S2). We note for instance that (1) based on the
‘‘rigid adaptation’’ concept the amino acid at ligand position 159
can be quite variable in size and chemical nature, (2) Asp163 is
conserved in all NKG2D ligands, and (3) alanine and glycine
dominate at position 162.
Unlike NKG2D, UL16 engages only MICB, ULBP1, ULBP2
and ULBP6, but not MICA, ULBP3, ULBP4 and ULBP5
[18–20,29–31]. Our SPR measurements show that UL16 binds
MICB with high affinity, whereas the affinity of UL16 for MICA is
negligible (Table S1), in line with earlier studies [2,21,29]. Given
the high degree of similarity between MICA and MICB at the
sequence and structural level, the inability of UL16 to engage
MICA is puzzling. In order to better understand the structural
parameters that guide UL16 binding to MICB vs. MICA, Spreu
et al. [29] assayed binding of soluble UL16-Fc to MICB chimeras
in which they had exchanged domains, subdomains and single
amino acids of MICB against equivalent regions of MICA. These
experiments clearly demonstrated that recognition by UL16 is
linked to residues projecting from the helical structures in the
MICB a2-domain. However, the molecular mechanism by which
these residues confer selectivity remained unclear.
The crystal structure of the UL16-MICB complex now allows us
to identify the key determinants of NKG2D ligand binding to UL16.
Our structural alignment of MICA and MICB identifies only seven
MICB residues that contact UL16 in the complex and that are
replaced by other amino acids in MICA (Figure 3A). Residues at
positions 64, 71, 75, 102 and 158 can assume alternate conforma-
tions that would not interfere with binding, and could in some cases
even mediate favorable contacts with UL16. Therefore, their effect
on UL16 binding is likely to be negligible (see also Ref. [29]).
Replacement of a1-domainGlu68 with glycine(Figure 4C) inMICA
would eliminate several hydrophobic contacts and three hydrogen
bonds with UL16 residues 117 and 118, and could therefore
conceivably have a negative effect on UL16 binding. However, as
complete replacement of the a1-domain of MICB by MICA
(including residue Glu68) did not significantly affect UL16 binding
[29], residue 68 is probably not a key determinant of UL16 binding.
On the other hand, however, Gln169 in the a2-domain of MICB
is likely to be critical. Our structure shows that substitution of
Gln169 with arginine, which is present at this position in MICA,
would lead to steric clashes with UL16 residues Met59 and Leu161
(Figure 6A) that would prevent binding. Thisis in perfectagreement
Figure 5. Comparison of the UL16-MICBpf and NKG2D-MICA
complex structures. In all panels, the two NKG2D monomers are
shown in salmon and green, whereas UL16 and MICBpf are colored blue
and orange, respectively. (A), Superposition of the UL16-MICBpf
complex onto the MICA-NKG2D complex [26]. MICA, which is very
similar to MICB, is not shown for clarity. (B), Ribbon drawings of the
a1a2-platform domains of MICA (left side, yellow) and MICB (right side,
orange), with their molecular surfaces outlined in grey. Surface-exposed
areas of residues that are buried upon complex formation with NKG2D
and UL16, respectively, are colored using the color scheme of panel (A).
MICB/MICA residues 155, 158, 159, 162 and 163, which contact both
UL16 and NKG2D in a similar manner are shown in darker green and
blue shading, respectively. (C), Structural mimicry of UL16. Close-up
view of the core region of the structures shown in panel (A) with UL16
residues Ile63, Lys123, Tyr125, Leu110, Leu114 that superimpose with
chemically equivalent NKG2D residues Ile182, Lys197, Tyr199, Met184
and Tyr152. Side chain atoms, UL16-MICBpf contacts, and water
molecules are colored as described in the legend to Figure 4.
doi:10.1371/journal.ppat.1000723.g005
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Gln169Arg substitution no longer bound UL16 [29]. We consider it
in fact likely that the side chain at position 169 is not only the key
determinant of selective UL16 binding to the MIC molecules but all
NKG2D ligands, which is based on the following reasons. (1) All
NKG2D ligands that carry a glutamine or glutamate at position
169, i. e. MICB, ULBP1, ULBP2 and ULBP6, bind UL16, while all
ligands that have an arginine at this position, i. e. MICA, ULBP3
and ULBP4, do not bind UL16 (Figure 3A). Although ULBP5 also
carries a glutamate at position 169 and should therefore bind UL16,
Wittenbrink et al. demonstrated by mutational studies that a
substitution in the a2-domain, which is unique among all NKG2D
ligands (Figure 3A), prevents binding of ULBP5 to UL16 [31]. (2)
Arg169 has a similar conformation, stabilized by contacts with
surrounding hydrophobic residues, in the unliganded [27] and
liganded [26] MICA structures (Figure 6A). In this orientation,
however, the Arg169 side chain would clash with UL16 residues.
Modeling suggests that the arginine side chain could adopt only a
single rotamer conformation, sandwiched between the hydrophobic
side chain regions of Leu172 and Lys173, that would not result in
steric clashes with UL16 (Figure 6A). However, such a rotamer is
only seen in 2% of all observed arginines [49]. (3)The conformation
of Arg169 in the ULBP3 structure [28], which is held in place by a
salt bridge to Asp170, would also clash with UL16 (Figure 6A). A
similar arrangement of Arg169 can be expected for ULBP4, where
Asp170 is replaced with glutamate (Figure 3A). We note that
Arg169 is not located near the NKG2D binding site and therefore
does not play a role in the interaction of either MICA or ULBP3
with NKG2D.
A second important requirement for binding of NKG2D ligands
to UL16 is the presence of a small hydrophobic side chain at
position 162. In the UL16-MICBpf complex, Ala162 faces towards
Tyr125, a UL16 footprint residue (Figures 5C and 6B). With the
exception of ULBP3, which has an arginine at this position, all
other NKG2D ligands have either an alanine or a glycine at
position 162 (Figures 3A and S2). The long and positively charged
Arg side chain of ULBP3 would clash with several UL16 residues
(Figure 6B), likely contributing to the failure of UL16 to bind
ULBP3 [2,17,18,21] (Table S1). Interestingly, Arg162 would also
clash with Met184 of the L2-loop of NKG2D in its MICA-
liganded form. To allow for ULBP3 binding, NKG2D undergoes
a conformational adjustment in which the L2-loop displaces
Met184, resulting in sufficient space for the accommodation of
Arg162 (Figure 6B). However, the rigid DEB b-sheet of UL16,
which would not allow for such larger conformational adjustments,
is unlikely to accommodate Arg162.
Taken together, these analyses suggest that some NKG2D
ligands apparently bypass intracellular retention by UL16 through
alteration of a small number of key residues at strategic locations of
their potential UL16 binding interface. We therefore consider it
likely that the selective pressure exerted by UL16 contributed to
drive the diversification of NKG2D ligands, which eventually may
have led to the emergence of non-UL16 binding ligands such as
MICA and ULBP3 [2,5,17,18,23]. Further support for an HCMV-
driven diversification of NKG2D ligands comes from studies by
Cosman and colleagues showing that the HCMV immunoevasin
UL142 targets most MICA allelic variants except MICA*08
[2,5,22]. Intriguingly, MICA*08 contains a truncated cytoplasmic
domain and is by far the most frequent MICA variant in many
populations [22]. As yet, no direct interaction of UL142 and MICA
has been shown and the molecular mechanisms of MICA
sequestration by UL142 are unknown. In contrast to UL16,
UL142 and MCMV-encoded immunoevasins m145, m152, and
m155 that suppress surface expression of mouse NKG2D ligands
MULT-1, RAE-1, and H60, respectively, are predicted to have an
MHC class I-like fold [2,22,23,50–54]. It will be of great interest to
determine the structural basis of NKG2D ligand engagement by
MHC class I-like HCMV immunoevasins and to compare these
interactions of two MHC class I-like molecules to those of the
NKG2D-like ligand binding mode of UL16.
NK receptors binding to MHC class I or class I-like molecules
belong to two structurally distinct families, the Ig superfamily and
Figure 6. Selectivity of NKG2D ligand binding by UL16. (A), The a1a2-platform domain of NKG2D-bound MICA [26] was superimposed onto
MICBpf, but only the MICA side chains Arg170 (pink) and Arg169 (magenta) are shown. The a1a2-domain of NKG2D-bound ULBP3 [28] was also
superposed onto MICB, and only the ULBP3 side chains of Arg169 (green) and Asp170 (light green) are shown. Cages surrounding the two arginines
of MICA and ULBP3 at position 169 depict the area that these side chains would require in a space-filling model. In both cases, the arginine side
chains would clash with UL16 residues. (B), The a1a2-platform domain of NKG2D-bound MICA [26] (yellow) and ULBP3 [28] (red), respectively, was
superimposed onto MICBpf (orange). The side chains of alanine (present in MICBpf and MICA) and arginine (present in ULBP3) at position 162 are
shown. Also shown are the Met184 side chains of both the MICA-bound (white) and ULBP3-bound (green) NKG2D monomers, both of which
correspond to the green NKG2D monomer in Figures 5A and 5B. Conformational changes of the L2-loop of MICA-bound NKG2D displaces Met184
and allows for the accommodation of Arg162 in ULBP3-bound NKG2D. In UL16, the rigid DEB sheet does not allow for a similar conformational
adjustment, and ULBP3 residue Arg162 would therefore clash with UL16 residues.
doi:10.1371/journal.ppat.1000723.g006
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latter group, our structural analysis shows that UL16 assumes an
Ig-like fold. Therefore, one may ask whether UL16 is related to
the Ig-like NK receptors that bind MHC class I molecules, such
as the leukocyte Ig-like receptors (LIRs) or the killer immuno-
globulin-like receptors (KIRs). Structures of LIR-1 in complex
with HLA-A2 [10] and with the HCMV MHC class I decoy
UL18 [45] show that, in both cases, LIR-1 contacts b2-
microglobulin and the a3-domain of the HLA-A2 and UL18
ligands via loops located at the interdomain hinge region of its
two tandem Ig domains. In contrast KIRs, like UL16, engage the
a-helical parts of the platform domain of MHC class I molecules,
but, similar to LIRs, employ loops at the interdomain hinge
region of their Ig domains for this interaction [10]. Therefore,
LIRs and KIRs exhibit an MHC class I-binding mode that is
distinct from that used by UL16. Since there is also no obvious
sequence homology between these Ig-like NK receptors and
UL16, we favor the view that UL16 evolved independently,
mimicking a central binding motif of the structurally unrelated
NKG2D immunoreceptor.
To the best of our knowledge, the structure presented here is the
first structure of a viral immunoevasin in complex with a
stimulatory NK receptor ligand as well as the first reported case
of structural mimicry through convergent evolution of a human
immunoreceptor by a viral immunoevasin. The results of our
structural analyses revealed that HCMV and humans indepen-
dently evolved two structurally distinct receptors, NKG2D and
UL16, that share the same central ligand binding motif in order to
achieve promiscuous binding to MIC and ULBP molecules. Our
findings provide new insights into the structural basis of the
evolutionary struggle between persistent viruses and cellular
immune surveillance, exemplified by the promiscuous binding
mode of the HCMV immunoevasin UL16 and the diversification
of NKG2D ligands.
Materials and Methods
Expression and purification
Expression and purification of UL16. A recombinant
cDNA fragment including the N-terminal signal peptide (residues
1–26) and the ectodomain (residues 27–184) of UL16 (GI: 9625700;
UniProt P16757) was fused to a thrombin cleavage site followed by
the human IgG1-Fc sequence and cloned into a pcDNA3.1
(2)
vector (Invitrogen). CHO Lec 3.2.8.1 cells [34] were stably
transfected with this construct using Lipofectamine 2000
(Invitrogen), and selected with 1.5 mg/ml G418 (Invitrogen) in a-
MEM, supplemented with 10% Ultra-Low IgG FCS (Invitrogen),
100 U/ml penicillin (PAA), 100 mg/ml streptomycin (PAA), 2 mM
L-glutamine (Invitrogen), and 1 mM pyruvate (PAA). A single cell
clone was selected and grown in roller bottles at 37uC and 5% CO2.
For each purification, 10 liters of cell culture supernatant were
filtered through a 0.2 mm filter, adjusted to pH 9 with 5 M NaOH,
and loaded overnight onto two serially connected Protein A HP
columns (5 ml column volume each; GE Healthcare) using an A ¨kta
FPLC system (GE Healthcare). The columns were extensively
washed with Protein A binding-buffer (500 mM NaCl, 170 mM
glycine pH 9 at 4uC) and the protein eluted with arginine-buffer
(10 mM NaCl, 500 mM arginine pH 4.1 at 4uC) directly into
reservoir-buffer (500 mM HEPES pH 9 at 4uC). Fractions
containing UL16 were pooled, dialysed against TBS (pH 8 at
22uC), and concentrated. Thrombin (Sigma) cleavage was
performed with 1 U/mg recombinant protein at 22uC for
18 hours. The cleaved samples were diluted five-fold in Protein A
binding-buffer and run over two consecutive Protein A HP columns
(1 ml column volume each; GE Healthcare) followed by a
benzamidine column (1 ml column volume; GE Healthcare) to
remove cleaved Fc tag and thrombin, respectively. Flow-through
containing UL16 was concentrated and dialyzed against TBS
(pH 7.4 at 4uC) for storage. UL16 migrated as a single band on
reducing SDS gels, but appeared as two bands, corresponding to
monomers and dimers, on non-reducing gels. Dimeric UL16 did
not bind MICB and could not be converted to monomer by
incubation with reducing agents. The dimer was separated from the
monomer with hydrophobic interaction chromatography (HIC).
Briefly, the UL16 monomer/dimer mixture was diluted in HIC-
binding buffer (1 M NaCl, 0.05 M Na2HPO4 pH 7.4 at 4uC),
loaded onto 3 serially connected phenyl sepharose columns (5 ml
column volume each; GE Healthcare), and washed extensively with
HIC-binding buffer. Phenyl-sepharose bound monomer was eluted
with HIC-elution buffer (0.05 M Na2HPO4 pH 7.4 at 4uC) and
dialysed against TBS pH 7.4 at 4uC. The yield of monomeric UL16
was 0.2 mg per 1 liter of cell culture supernatant.
Expression and purification of MICB. Gene sequences
(GI:2454261; UniProt Q29980) encoding ectodomains a1 and a2
of MICB*02 (MICBpf, residues 1–181) and ectodomains a1, a2
and a3 of MICB*02 (residues 1–276) were fused to a thrombin
cleavage site followed by (His)8- and (His)6-tags, respectively, and
cloned into the pET-21a(+) vector (Novagen). Both proteins were
purified with the same strategy. E.coli Rosetta2 cells transformed
with the appropriate expression construct were grown in LB
medium, supplemented with 50 mg/ml ampicillin and 34 mg/ml
chloramphenicol, to an optical density (OD)600 of 0.6 before
induction with 1 mM IPTG at 37uC for 12 hours. Inclusion
bodies containing MICB were refolded by stepwise arginine/urea
dialysis. Soluble MICB in TBS (pH 7.4 at 4uC) was further
purified via Ni-NTA affinity chromatography (1 ml column
volume; GE Healthcare) followed by Superdex 75 size-exclusion
chromatography (GE Healthcare).
Complex formation. UL16 and an excess amount of
MICBpf were incubated for 16 hrs in TBS pH 7.4 at 4uC. The
complex was separated from excess MICB through gel filtration
(Superdex 75). In order to obtain diffracting crystals, UL16 was
deglycosylated by incubation with EndoH after complex formation.
Briefly, complex was diluted in EndoH-buffer (0.1 M NaAc pH 5.2
at 25uC), containing 0.5 U/ml EndoH (NEB) and incubated for 1 h
at 37uC. Removal of cleaved glycans and EndoH was performed by
size exclusion chromatography (Superdex 75). The complex was
then concentrated to 15 mg/ml and used for crystallization.
Surface plasmon resonance
All SPR experiments were performed and evaluated as
described previously [55]. Using two consecutive flow cells on a
CM5 biosensor chip, MICBa1a2 (MICBpf) and MICBa1a3
ligands, respectively, were each covalently immobilized on the
surface of the downstream (experimental) flow cell via amine-
coupling chemistry (GE Healthcare) following manufacturer’s
instructions, while the surface of the upstream (reference) flow cell
was subjected to the same coupling reaction in the absence of
protein. For the Protein A-G chip preparation, an amount of 3500
RU (resonance units) of recombinant Protein A-G (BioVision) was
covalently immobilized to the upstream (reference) and down-
stream (experimental) flow cells of a CM5 biosensor chip (GE
Healthcare) by amine-coupling chemistry (GE Healthcare). Fc-
tagged ULBP1, ULBP2, ULBP3 (all R&D Systems), ULBP4 and
ULBP5 ligands [31] were diluted in HBS-EP (10 mM HEPES,
150 mM NaCl, 3 mM EDTA, 0.005% (v/v) Surfactant P20,
pH 7.4 at 25uC) and noncovalenty bound to the experimental flow
cell surface. In all experiments, untagged, monomeric UL16
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over the reference- and experimental biosensor surface at 50 ml/
min. After each cycle using a Protein A-G chip, the biosensor
surface was regenerated (stripped of any remaining analyte and
ligand) with two 1 min injections of 10 mM glycine pH 1.7. CM5
chips were not regenerated.
Crystallization
For crystallization, complex at 15 mg/ml was mixed in a 1:1
ratio with a reservoir solution containing 0.2 M ammonium
sulfate, 0.1 M sodium cacodylate pH 6.5, and 25% PEG 8000.
Crystals grew at 4uC over a time period of 4 months using the
hanging drop vapor diffusion method. They were soaked in
reservoir solution enriched with 15% ethylene glycol, and then
flash frozen in liquid nitrogen prior to data collection.
Structure determination
The crystals belong to space group P212121 and contain two
complexes in the asymmetric unit. All diffraction data were
collected at 100 K and a wavelength of 1.0013 A ˚ at the Swiss
Light Source (SLS, Villigen, Switzerland) beamline X06SA using
the PILATUS 6M detector. Data were indexed, integrated and
scaled with XDS [56], and the structure was solved by molecular
replacement as implemented in PHASER [57] using the
unliganded MICB structure [25] (PDB code 1JE6) as search
model. The initial density map already clearly showed the
approximate location of the UL16 molecules. Phases were then
improved through non-crystallographic symmetry averaging using
RESOLVE [58]. Structural refinement was performed with
PHENIX [59] and model building was done with Coot [49].
Refinement included TLS-refinement of 26 TLS groups assigned
by the TLSMD Server [60]. A data set for Rfree calculation was
generated with 5% randomly selected reflections, and refinement
progress was monitored by the decrease of R and Rfree throughout.
The final model has R and Rfree values of 17.7% and 21.5%,
respectively, and was validated using PROCHECK [57] and
WHAT_IF [61]. Secondary structure elements were assigned with
DSSP [62]. Structural figures were created with PyMOL [63].
Glycan modeling
Eight potential N-linked glycosylation sites were identified in the
UL16 ectodomain. Six of the possible eight asparagine residues
(Asn41, 68, 84, 95, 101, 132) carry NAG residues that are clearly
defined by electron density (Figure 1A). While extra density is
present at the seventh residue, Asn35, this density is not well
defined, and no NAG residue was built at this location. No extra
electron density is observed at the final asparagine, Asn145, and
thus this residue is either not glycosylated or carries an especially
flexible glycan moiety. We note that Asn145 is close in space to
Asn35, which is glycosylated. In order to produce a realistic
estimate of size and distribution of the glycan structure of native
UL16 (Figure 1B) we used the GlyProt [64] online server and
modeled hybrid and complex glycans linked to the seven Asn
residues with NAG electron density.
Accession numbers
Atomic coordinates and structure factors have been deposited
with the Protein Data Bank under accession code 2wy3.
Supporting Information
Table S1 Kinetic and affinity data determined by SPR
Found at: doi:10.1371/journal.ppat.1000723.s001 (0.04 MB
DOC)
Figure S1 Schematic view of the structural mimicry of UL16.
T h eb l u er e g i o n sh i g h l i g h tt h ef i v eU L 1 6a n dN K G 2 Df o o t p r i n t
residues participating in structural mimicry. UL16 residues are
shown in white, the corresponding NKG2D residues are shown
in black. MICA and MICB residues that are contacted by the
footprint are placed in yellow circles, at the approximate
position of interaction. Also shown are the amino acids at
corresponding positions in ULBP1, ULBP5/6, ULBP2, ULBP3
and ULBP4. In ULBP3 [28], a kink in the a3-helix starting at
position 162 (Figure 6B) causes a one-residue shift towards the
N-terminus. In these cases, the shifted ULBP3 residue that
corresponds to the MICBpf residue is given by a superscript
number following the ULBP3 one letter code. As an example,
ULBP3 position Met168 and not Val169 corresponds to
MICBpf position Ala159. Also as a result of the helix kink, no
ULPB3 residue corresponds in space to the MICBpf residue in
position 155, indicated by (#). Interactions between residues are
represented with arrows, accompanied by green text for
hydrogen bonds, red text for salt bridges, and magenta text
for hydrophobic contacts; the blue text indicates the clash of
ULBP3 Arg162 (Figure 3A) with Leu100 of UL16 or Met184 of
NKG2D as observed in the MICA/NKG2D complex structure
[26] (Figure 6B).
Found at: doi:10.1371/journal.ppat.1000723.s002 (0.96 MB
TIF)
Figure S2 Schematic view of the structural mimicry of UL16.
T h eb l u er e g i o n sh i g h l i g h tt h ef i v eU L 1 6a n dN K G 2 Df o o t p r i n t
residues participating in structural mimicry. UL16 residues are
shown in white, the corresponding NKG2D residues are shown
in black. MICA and MICB residues that are contacted by the
footprint are placed in yellow circles, at the approximate
position of interaction. Also shown are the amino acids at
corresponding positions in ULBP1, ULBP5/6, ULBP2, ULBP3
and ULBP4. In ULBP3 [28], a kink in the a3-helix starting at
position 162 (Figure 6B) causes a one-residue shift towards the
N-terminus. In these cases, the shifted ULBP3 residue that
corresponds to the MICBpf residue is given by a superscript
number following the ULBP3 one letter code. As an example,
ULBP3 position Met168 and not Val169 corresponds to
MICBpf position Ala159. Also as a result of the helix kink, no
ULPB3 residue corresponds in space to the MICBpf residue in
position 155, indicated by (#). Interactions between residues are
represented with arrows, accompanied by green text for
hydrogen bonds, red text for salt bridges, and magenta text
for hydrophobic contacts; the blue text indicates the clash of
ULBP3 Arg162 (Figure 3A) with Leu100 of UL16 or Met184 of
NKG2D as observed in the MICA/NKG2D complex structure
[26] (Figure 6B).
Found at: doi:10.1371/journal.ppat.1000723.s003 (0.45 MB
TIF)
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